Potential predictive markers in protocol biopsies for premature renal graft loss

Kidney and Blood Pressure Research

Volumn 33, Issue 1, 2010, Pages 7-14

  Matl, Ivo ^a   Hribova, Petra ^b   Honsova, Eva ^c   Brabcova, Irena ^b   Klicky, Ondrej ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Transplant Laboratory   (Czech Republic)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Borderline changes; Chemokines; Cytokines; Gene expression; Subclinical rejection

Indexed keywords

CREATININE; MESSENGER RNA; RANTES;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GRAFT FAILURE; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; ANTIGENS, CD20; ANTIGENS, CD3; BIOLOGICAL MARKERS; BIOPSY; CHEMOKINE CCL5; CHEMOKINE CXCL10; COMPLEMENT C3; CREATININE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER;

EID: 74249086148     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275705     Document Type: Article

References (42)

1. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR: Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515-523.
2. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J: Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129-2134.
3. Scholten EM, Rowshani AT, Cremers S, Bemelman FJ, Eikmans M, van Kan E, Mallat MJ, Florquin S, Surachno J, ten Berge IJ, Bajema IM, de Fijter JW: Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006; 17: 2622-2632.
4. Halloran PF: Call for revolution: a new approach to describing allograft deterioration. Am J Transplant 2002; 2: 195-200.
5. Chapman JR, O'Connell PJ, Nankivell BJ: Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026.
6. Tullius SG, Tilney NL: Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313-318.
7. Baan CC, Weimar W: Intragraft cytokine gene expression: implications for clinical transplantation. Transplant Int 1998; 11: 169-180.
8. Hribova P, Kotsch K, Brabcova I, Vitko S, Volk HD, Lacha J: Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc 2005; 37: 760-763.
9. Melk A, Henne T, Kollmar T, Strehlau J, Latta K, Offner G, Jhangri GS, Ehrich JH, Von Schnakenburg C: Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. Kidney Int 2003; 64: 314-320.
10. Hribova P, Lacha J, Kotsch K, Volk HD, Brabcova I, Skibova J, Vitko S, Viklicky O: Intrarenal cytokine and chemokine gene expression and kidney graft outcome. Kidney Blood Press Res 2007; 30: 273-282.
11. Pribylova-Hribova P, Kotsch K, Lodererova A, Viklicky O, Vitko S, Volk HD, Lacha J: TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int 2006; 69: 1872-1879.
12. Viklicky O, Hribova P, Volk HD, Slatinska J, Petrasek J, Bandur S, Honsova E, Reinke P: Molecular phenotypes of acute rejection predict kidney graft prognosis. J Am Soc Nephrol 2009;in press.
13. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
14. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ: Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
15. Vincenti F: A decade of progress in kidney transplantation. Transplantation 2004; 77: S52-S61.
16. Nankivell BJ, Chapman JR: The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 2006-2012.
17. Helantera I, Ortiz F, Helin H, Raisanen-Sokolowski A, Honkanen E, Koskinen P: Timing and value of protocol biopsies in wellmatched kidney transplant recipients: a clinical and histopathologic analysis. Transplant Int 2007; 20: 982-990.
18. Kee TY, Chapman JR, O'Connell PJ, Fung CL, Allen RD, Kable K, Vitalone MJ, Nankivell BJ: Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation 2006; 82: 36-42.
19. Seron D, Moreso F, Ramon JM, Hueso M, Condom E, Fulladosa X, Bover J, Gil-Vernet S, Castelao AM, Alsina J, Grinyo JM: Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 1849-1855.
20. Tichy T, Tichy M, Zadrazil J, Krejci K, Horcicka V Jr, al-Jabry S, Bachleda P, Kral V, Dusek J: Histologic findings in protocol biopsies of transplanted kidneys. Cesk Patol 2003; 39: 11-16.
21. Rush D: Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 138-143.
22. Koo DD, Roberts IS, Quiroga I, Procter J, Barnardo MC, Sutton M, Cerundolo L, Davies DR, Friend PJ, Morris PJ, Fuggle SV: C4d deposition in early renal allograft protocol biopsies. Transplantation 2004; 78: 398-403.
23. Sund S, Hovig T, Reisaeter AV, Scott H, Bentdal O, Mollnes TE: Complement activation in early protocol kidney graft biopsies after living-donor transplantation. Transplantation 2003; 75: 1204-1213.
24. Choi BS, Shin MJ, Shin SJ, Kim YS, Choi YJ, Kim YS, Moon IS, Kim SY, Koh YB, Bang BK, Yang CW: Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5: 1354-1360.
25. Kanetsuna Y, Yamaguchi Y, Toma H, Tanabe K: Histological evaluation of renal allograft protocol biopsies in the early period and 1 year after transplantation. Clin Transplant 2003; 17(suppl 10):25-29.
26. Mengel M, Gwinner W, Schwarz A, Bajeski R, Franz I, Brocker V, Becker T, Neipp M, Klempnauer J, Haller H, Kreipe H: Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2007; 7: 356-365.
27. Margreiter R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746.
28. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
29. Gloor JM, Cohen AJ, Lager DJ, Grande JP, Fidler ME, Velosa JA, Larson TS, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Sterioff S, Kremers WK, Stegall MD: Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002; 73: 1965-1968.
30. Moreso F, Alperovich G, Fulladosa X, Gil- Vernet S, Ibernon M, Carrera M, Castelao AM, Hueso M, Grinyo JM, Seron D: Histologic findings in protocol biopsies performed in stable renal allografts under different immunosuppressive schedules. Transplant Proc 2003; 35: 1666-1668.
31. Rush DN, Jeffery J, Gough J, Grimm P, Lipman M, Birk P, McKenna R, Nickerson P: Predicting rejection: is early diagnosis achievable and important? Graft 1999; 2: 31.
32. Bohmig GA, Regele H, Horl WH: Protocol biopsies after kidney transplantation. Transplant Int 2005; 18: 131-139.
33. Furness PN, Philpott CM, Chorbadjian MT, Nicholson ML, Bosmans JL, Corthouts BL, Bogers JJ, Schwarz A, Gwinner W, Haller H, Mengel M, Seron D, Moreso F, Canas C: Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 2003; 76: 969-973.
34. Flechner SM, Kurian SM, Head SR, Sharp SM, Whisenant TC, Zhang J, Chismar JD, Horvath S, Mondala T, Gilmartin T, Cook DJ, Kay SA, Walker JR, Salomon DR: Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4: 1475-1489.
35. Strehlau J, Pavlakis M, Lipman M, Shapiro M, Vasconcellos L, Harmon W, Strom TB: Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695-700.
36. Kirk AD, Jacobson LM, Heisey DM, Radke NF, Pirsch JD, Sollinger HW: Clinically stable human renal allografts contain histological and RNA-based findings that correlate with deteriorating graft function. Transplantation 1999; 68: 1578-1582.
37. Lipman ML, Shen Y, Jeffery JR, Gough J, McKenna RM, Grimm PC, Rush DN: Immune- activation gene expression in clinically stable renal allograft biopsies: molecular evidence for subclinical rejection. Transplantation 1998; 66: 1673-1681.
38. Veronese FV, Noronha IL, Manfro RC, Edelweiss MI, Goldberg J, Goncalves LF: Prevalence and immunohistochemical findings of subclinical kidney allograft rejection and its association with graft outcome. Clin Transplant 2004; 18: 357-364.
39. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O Jr: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125-138.
40. Tsai EW, Rianthavorn P, Gjertson DW, Wallace WD, Reed EF, Ettenger RB: CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation 2006; 82: 1769-1773.
41. Itadani H, Mizuarai S, Kotani H: Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics 2008; 9: 349-360.
42. Schmid H, Henger A, Kretzler M: Molecular approaches to chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15: 123-129.